The plasma derivatives multinational Grifols is up 5.80% on the stock market after presenting its results to September, in which it has left behind the red numbers of the first part of the year and has achieved a profit of 3.3 million, 98% less than in the same period last year, thanks to the increase in revenue.
A quarter of an hour after the opening of the market, Grifols is the most advanced stock in the Spanish selective index, IBEX 35, and the share price stands at 11.15 euros after rising by 5.80 %.
At this hour, the IBEX 35 is up 78.19 points, 0.87%, and stands at 9,154.
Grifols’ total income has increased to 4,822 million euros, 11.7% more in the first nine months of this year, with the boost from Biopharma, of which 1,597 million euros corresponds to the last quarter, a 9% increase, as reported Thursday in a statement by the company.
According to Bankinter analysts, Grifols’ results have not presented any surprises and have met expectations. Therefore, it maintains a neutral position on the company and has revised its target price from 13.20 euros per share.
Grifols earns 3.3 million euros in the first nine months of the year, 98% less than a year earlier
The plasma derivatives multinational Grifols has left behind the red numbers of the first part of the year and has achieved a profit of 3.3 million euros up to September, 98% less than in the same period last year, thanks to the increase in revenue.
Total revenues rose to 4.822 billion euros, up 11.7% in the first nine months of this year, boosted by Biopharma, of which 1.597 billion euros corresponded to the last quarter, up 9%, the company said in a statement on Thursday.
The driving force of its business, plasma supply, grew by 10%, while cost per litre continued to fall by 22%, after implementing the operational improvement plan to save costs, and turn around the 56 million euro loss in the first half of the year.